statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Innoviva, Inc. (Nasdaq: INVA) (Innoviva or the Company), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

Innoviva, Inc. (NASDAQ: INVA) (Innoviva or the Company), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva...

Innoviva to Participate in the BofA Securities Health Care Conference

13,271 Shares in Innoviva, Inc. (NASDAQ:INVA) Purchased by Ritholtz Wealth Management

Ritholtz Wealth Management bought a new stake in shares of Innoviva, Inc. (NASDAQ:INVA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the...

Innoviva (NASDAQ:INVA) Rating Increased to Buy at StockNews.com

Innoviva (NASDAQ:INVA - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.
Separately, TheStreet...

Pacer Advisors Inc. Buys 1,727,534 Shares of Innoviva, Inc. (NASDAQ:INVA)

Pacer Advisors Inc. boosted its stake in Innoviva, Inc. (NASDAQ:INVA  Free Report) by 119,140.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and...

Innoviva (INVA, $14.99) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 21, 2024

This is a Bullish indicator signaling INVA's price could rise from here. Traders may explore going long the stock or buying call options...

Innoviva (INVA, $14.63) RSI Indicator left the oversold zone on March 19, 2024

This is a signal that INVA's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

Innoviva (INVA, $14.56) RSI Indicator left the oversold zone on March 18, 2024

Innoviva, Inc. (NASDAQ:INVA) Sees Large Growth in Short Interest

Innoviva, Inc. (NASDAQ:INVA  Get Free Report) was the target of a large growth in short interest during the month of February. As of February 29th, there was short interest totalling...

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Volume	500,720.00
52-Wk High	$18.56
52-Wk Low	$12.22

INVA Innoviva Inc

About

Feed

News

Sentiment

Earnings

Fundamentals